Mussel adhesive protein/HA coacervate |
MSCs |
Increased MSCs survival and retention |
[92] |
Collagen-based hydrogel |
ADSCs |
Improved engraftment of stem cells |
[93] |
Microcapsules made of agarose and ECM components |
MSCs |
Increased MSCs survival |
[94] |
Arginylglycylaspartic acid (RGD) modified HA hydrogel |
MSCs |
Increased MSCs survival |
[95] |
Erythropoietin linked hydrogel |
iPSCs |
Improved the post-MI heart recovery |
[96] |
Synthetic SAP and angiopoetin-1-derived pro-survival peptide QHREDGS |
MSCs |
Increased cells survival and cardiac function |
[97] |
Collagen–dendrimer |
CPCs |
Increased long-term survival |
[99] |
Silica-coated SOMag5 magnetic nanoparticles |
Embryonic cardiomyocytes, embryonic stem cell-derived cardiomyocytes and BMSCs |
Improved cell engraftment |
[100] |
Graphene oxide/alginate microgel |
MSCs |
Improved MI recovery |
[101] |
Poly(ε-caprolactone)/gelatin patch |
MSCs |
Increased angiogenesis, lymphangiogenesis, cardiomyogenesis, and paracrine factors released by stem cells and reduced scar size |
[103] |
Chitosan and silk fibroin microfibrous cardiac patch |
MSCs |
Increased MSC survival |
[104] |
Hyaluronic acid/gelatin cardiac patch |
CPCs |
Increased long-term CPCs survival and differentiation |
[105] |
Vascularized fibrin hydrogel patch |
CSCs |
Increased cell survival |
[106] |
Gold nanoparticles coated with a combination of ECM and silk proteins |
MSCs |
Increased cell survival and retention and decreased infarct size |
[107] |
ECM scaffold with the usage of methacrylated gelatin |
iPSC-derived cardiomyocytes, smooth muscle cells and endothelial cells |
Reduced infarct size and improved cell proliferation, cardiac function, and angiogenesis |
[108] |
Poly(vinyl alcohol) microneedle patch |
CSCs |
Improved angiogenesis, reduced fibrosis, and repaired left ventricular wall |
[109] |
Polycaprolactone patch |
MSCs and iPSC-derived cardiomyocytes |
Improved MI recovery and angiogenesis |
[110] |
Microchanneled poly(ethylene glycol) dimethacrylate hydrogel patch |
MSCs |
Improved cardiac function |
[112] |
Agarose hydrogel microcapsules supplemented with fibronectin and fibrinogen |
CSCs |
Improved production of pro-angiogenic/cardioprotective cytokines, angiogenesis, and angiogenic cells recruitment after direct intramyocardial injection |
[113] |
Iron nanoparticles |
MSCs |
Reduced the infarct size, prevented fibrosis, decreased apoptosis of myocardial cells, increased angiogenesis, and improved cardiac function |
[115] |
Statin-conjugated poly(lactic-co-glycolic acid) nanoparticles |
ADSCs |
Increased the ejection fraction and several other parameters which reflect the left ventricular function. Inhibited local inflammation, promoted recruitment of circulating stem cells, and stimulated their differentiation to cardiomyocytes and angiogenesis |
[121] |
Tetraaniline-polyethylene glycol diacrylate and thiolated hyaluronic acid conductive hydrogel |
ADSCs |
Improved neovascularization, regeneration of the damaged myocardium, and post-infarction cardiac function |
[17] |
Naphthalene hydrogel |
MSCs |
Increased cells survival, and stimulated the synthesis of angiogenic factors VEGF and SDF-1α |
[122] |
Poly(lactic-co-glycolic acid) microparticles |
ADSCs |
Improved cells survival, and induced the shift of macrophage found in the infarcted myocardium from pro-inflammatory M1 to regenerative M2 phenotype |
[123] |
Poly(l-lactic acid) mat |
CSCs |
Improved angiogenic and cardiomyogenic effects |
[124] |